In the present study, we evaluated the protein expression of Survivin by IHC in a total of 56 GBMs, including 30 primary and 26 secondary GBMs, and in 15 matched low-grade precursor lesions (grade II or III gliomas) of secondary GBMs. This evidence concerns the gene BIRC5 and central nervous system cancer.